At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
PF-06291874 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of Pf-06291874 Given As Monotherapy To Adults With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating Placebo and PF-06291874 for Diabetes Mellitus, Type II. Completed, enrolled 172 participants across 19 sites.
Detailed Summary
This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type II
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionMar 2015
TodayJul 2026
First PostedJun 26, 2014
Enrollment StartAug 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.0 years ago
Interventions
Placebodrug
Tablet, once daily for 28 days
PF-06291874drug
Tablet, 15 mg, once daily for 28 days
PF-06291874drug
Tablet, 35 mg, once daily for 28 days
PF-06291874drug
Tablet, 75 mg, once daily for 28 days
PF-06291874drug
Tablet, 150 mg, once daily for 28 days